Recent therapeutic approaches for Alzheimer’s disease (AD) have had limited success. Considering the association of neuroinflammation with AD symptoms as demonstrated in multiple studies, assessment of the clinical efficacy of molecules that reduce systemic or brain inflammation is warranted.
Objective:
This clinical trial assessed whether boswellic acids can improve cognitive and neuropsychiatric symptoms while reducing inflammation in AD patients.
Methods:
A double-blind, placebo-controlled, study was conducted on 85 AD patients randomized to boswellic acids (K-Vie™ as the main ingredient in Memowell™) or placebo for 6 months. Clinical Dementia Rating–Sum of Boxes (CDR-SOB) and Mini-Mental State Examination (MMSE) scores were compared to baseline and between groups and constituted the co-primary clinical efficacy endpoints. Secondary outcomes included neuropsychiatric assessment (Neuropsychiatric Inventory-Questionnaire, NPI-Q) and assessment of AD and inflammation biomarkers.
Results:
Patients on K-Vie™ showed a 3.1- and 1.6-unit improvement in MMSE and CDR-SOB scores, respectively, when compared to patients on placebo. NPI-Q analysis revealed significant improvement in the K-Vie™ but not in the placebo group. Only mild gastrointestinal side effects were reported in a few patients. Patients on K-Vie™ showed improvement in plasma AD biomarkers and reduction of key inflammatory cytokines including IL-6 and TNF.
Conclusion:
Our results support the positive cognitive effects of boswellic acids by reducing the systemic inflammation.
ZissimopoulosJ, CrimminsE, St. ClairP (2014) The value of delaying Alzheimer’s disease onset. Forum Health Econ Policy18, 25–39.
2.
SchneiderLS, MangialascheF, AndreasenN, FeldmanH, GiacobiniE, JonesR, MantuaV, MecocciP, PaniL, WinbladB, KivipeltoM (2014) Clinical trials and late-stage drug development for Alzheimer’s disease: An appraisal from 1984 to 2014. J Intern Med275, 251–283.
3.
CummingsJ, LeeG, RitterA, ZhongK (2018) Alzheimer’s disease drug development pipeline: 2018. Alzheimers Dement (N Y)4, 195–214.
4.
CummingsJ, LeeG, RitterA, SabbaghM, ZhongK (2019) Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement (N Y)5, 272–293.
5.
JackCR, HoltzmanDM (2013) Biomarker modeling of Alzheimer’s disease. Neuron80, 1347–1358.
6.
OlssonB, LautnerR, AndreassonU, ÖhrfeltA, PorteliusE, BjerkeM, HölttäM, RosénC, OlssonC, StrobelG, WuE, DakinK, PetzoldM, BlennowK, ZetterbergH (2016) CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis. Lancet Neurol15, 673–684.
7.
FanL-Y, TzenK-Y, ChenY-F, ChenT-F, LaiY-M, YenR-F, HuangY-Y, ShiueC-Y, YangS-Y, ChiuM-J (2018) The relation between brain amyloid deposition, cortical atrophy, and plasma biomarkers in amnesic mild cognitive impairment and Alzheimer’s disease. Front Aging Neurosci10, 175.
8.
FandosN, Pérez-GrijalbaV, PesiniP, OlmosS, BossaM, VillemagneVL, DoeckeJ, FowlerC, MastersCL, SarasaM, AIBL Research Group (2017) Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst)8, 179–187.
9.
Graff-RadfordNR, CrookJE, LucasJ, BoeveBF, KnopmanDS, IvnikRJ, SmithGE, YounkinLH, PetersenRC, YounkinSG (2007) Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol64, 354–362.
10.
KoyamaA, OkerekeOI, YangT, BlackerD, SelkoeDJ, GrodsteinF (2012) Plasma amyloid-β as a predictor of dementia and cognitive decline: A systematic review and meta-analysis. Arch Neurol69, 824–831.
11.
NisticòR, BorgJJ (2021) Aducanumab for Alzheimer’s disease: A regulatory perspective. Pharmacol Res171, 105754.
12.
VillainN, PlancheV, LevyR (2022) High-clearance anti-amyloid immunotherapies in Alzheimer’s disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects. Rev Neurol (Paris)178, 1011–1030.
13.
van DyckCH, SwansonCJ, AisenP, BatemanRJ, ChenC, GeeM, KanekiyoM, LiD, ReydermanL, CohenS, FroelichL, KatayamaS, SabbaghM, VellasB, WatsonD, DhaddaS, IrizarryM, KramerLD, IwatsuboT (2023) Lecanemab in early Alzheimer’s disease. N Engl J Med388, 9–21.
14.
SerotJM, ChristmannD, DubostT, CouturierM (1997) Cerebrospinal fluid transthyretin: Aging and late onset Alzheimer’s disease. J Neurol Neurosurg Psychiatry63, 506–508.
RibeiroCA, SantanaI, OliveiraC, BaldeirasI, MoreiraJ, SaraivaMJ, CardosoI (2012) Transthyretin decrease in plasma of MCI and AD patients: Investigation of mechanisms for disease modulation. Curr Alzheimer Res9, 881–889.
17.
VelayudhanL, KillickR, HyeA, KinseyA, GüntertA, LynhamS, WardM, LeungR, LourdusamyA, ToAWM, PowellJ, LovestoneS (2012) Plasma transthyretin as a candidate marker for Alzheimer’s disease. J Alzheimers Dis28, 369–375.
18.
MangalmurtiA, LukensJR (2022) How neurons die in Alzheimer’s disease: Implications for neuroinflammation. Curr Opin Neurobiol75, 102575.
19.
XieJ, Van HoeckeL, VandenbrouckeRE (2022) The impact of systemic inflammation on Alzheimer’s disease pathology. Front Immunol12, 796867.
20.
BradburnS, MurgatroydC, RayN (2019) Neuroinflammation in mild cognitive impairment and Alzheimer’s disease: A meta-analysis. Ageing Res Rev50, 1–8.
21.
ShenX-N, NiuL-D, WangY-J, CaoX-P, LiuQ, TanL, ZhangC, YuJ-T (2019) Inflammatory markers in Alzheimer’s disease and mild cognitive impairment: A meta-analysis and systematic review of 170 studies. J Neurol Neurosurg Psychiatry90, 590–598.
22.
ParkJ-C, HanS-H, Mook-JungI (2020) Peripheral inflammatory biomarkers in Alzheimer’s disease: A brief review. BMB Rep53, 10–19.
23.
OberlinLE, EricksonKI, MackeyR, KlunkWE, AizensteinH, LoprestiBJ, KullerLH, LopezOL, SnitzBE (2021) Peripheral inflammatory biomarkers predict the deposition and progression of amyloid-β in cognitively unimpaired older adults. Brain Behav Immun95, 178–189.
24.
FarshchiA, GhiasiG, FarshchiS, KhatabiP (2010) Effects of Boswellia Papyrifera gum extract on learning and memory in mice and rats. Iran J Basic Med Sci13, 9–15.
25.
Hosseini SharifabadM, EsfandiaryE (2007) A morphometeric study on CA3 hippocampal field in young rats following maternal administration of Boswellia Serrata resin during gestation. Iran J Basic Med Sci10, 176–182.
26.
Hosseini-sharifabadM, EsfandiariE (2015) Effect of Boswellia serrata gum resin on the morphology of hippocampal CA1 pyramidal cells in aged rat. Anat Sci Int90, 47–53.
27.
Hosseini-SharifabadM, Kamali-ArdakaniR, Hosseini-SharifabadA (2016) Beneficial effect of Boswellia serrata gum resin on spatial learning and the dendritic tree of dentate gyrus granule cells in aged rats. Avicenna J Phytomed6, 189–197.
28.
HosseiniM, ShafeiMN, SafariV, TaiaraniZ, Kafami LadaniM, SadeghianR (2012) The effects of olibanum administered to methimazole-treated dams during lactation on learning and memory of offspring rats. Nat Prod Res26, 1544–1548.
29.
MahmoudiA, Hosseini-SharifabadA, Monsef-EsfahaniHR, YazdinejadAR, KhanaviM, RoghaniA, BeyerC, SharifzadehM (2011) Evaluation of systemic administration of Boswellia papyrifera extracts on spatial memory retention in male rats. J Nat Med65, 519–525.
30.
BeheshtiS, AghaieR (2016) Therapeutic effect of frankincense in a rat model of Alzheimer’s disease. Avicenna J Phytomed6, 468–475.
31.
SharmaM, GuptaYK (2001) Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment. Life Sci68, 1021–1029.
32.
JaliliC, SalahshoorMR, PourmotabbedA, MoradiS, RoshankhahSH, DarehdoriAS, MotaghiM (2014) The effects of aqueous extract of Boswellia Serrata on hippocampal region CA1 and learning deficit in kindled rats. Res Pharm Sci9, 351–358.
33.
SedighiB, PardakhtyA, KamaliH, ShafieeK, HasaniBN (2014) Effect of Boswellia papyrifera on cognitive impairment in multiple sclerosis. Iran J Neurol13, 149–153.
34.
ZakerSR, BeheshtiS, AghaieR, NoorbakhshniaM (2015) Effect of olibanum on a rat model of Alzheimer’s disease induced by intracerebroventricular injection of streptozotocin. Physiol Pharmacol18, 477–489.
35.
StrefferJR, BitzerM, SchabetM, DichgansJ, WellerM (2001) Response of radiochemotherapy-associated cerebral edema to a phytotherapeutic agent, H15. Neurology56, 1219–1221.
36.
KirsteS, TreierM, WehrleSJ, BeckerG, Abdel-TawabM, GerbethK, HugMJ, LubrichB, GrosuA-L, MommF (2011) Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: A prospective, randomized, placebo-controlled, double-blind pilot trial. Cancer117, 3788–3795.
37.
BaramSM, KarimaS, ShateriS, TafakhoriA, FotouhiA, LimaBS, RajaeiS, MahdaviM, TehraniHS, AghamollaiiV, AghamiriSH, MansouriB, GharahjeS, KabiriS, HosseinizadehM, ShahamatiSZ, AlborziAT (2019) Functional improvement and immune-inflammatory cytokines profile of ischaemic stroke patients after treatment with boswellic acids: A randomized, double-blind, placebo-controlled, pilot trial. Inflammopharmacology27, 1101–1112.
38.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
39.
CummingsJL, MegaM, GrayK, Rosenberg-ThompsonS, CarusiDA, GornbeinJ (1994) The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology44, 2308–2314.
40.
KauferDI, CummingsJL, KetchelP, SmithV, MacMillanA, ShelleyT, LopezOL, DeKoskyST (2000) Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci12, 233–239.
41.
SiddiquiA, ShahZ, JahanRN, OthmanI, KumariY (2021) Mechanistic role of boswellic acids in Alzheimer’s disease: Emphasis on anti-inflammatory properties. Biomed Pharmacother144, 112250.
42.
GomaaAA, MakboulRM, Al-MokhtarMA, NicolaMA (2019) Polyphenol-rich Boswellia serrata gum prevents cognitive impairment and insulin resistance of diabetic rats through inhibition of GSK3β activity, oxidative stress and pro-inflammatory cytokines. Biomed Pharmacother109, 281–292.
43.
KarimaO, RiaziG, YousefiR, MovahediAAM (2010) The enhancement effect of beta-boswellic acid on hippocampal neurites outgrowth and branching (an in vitro study). Neurol Sci31, 315–320.
44.
SadeghniaHR, ArjmandF, GhorbaniA (2017) Neuroprotective effect of Boswellia Serrata and its active constituent acetyl-11-keto-β-boswellic acid against oxygen-glucose-serum-deprivation-induced cell injury. Acta Pol Pharm74, 911–920.
45.
LuCW, LinTY, WangSJ (2020) 11-Keto-β-Boswellic acid attenuates glutamate release and kainic acid-induced excitotoxicity in the rat hippocampus. Planta Med86, 434–441.
BlennowK, De MeyerG, HanssonO, MinthonL, WallinA, ZetterbergH, LewczukP, VandersticheleH, VanmechelenE, KornhuberJ, WiltfangJ, KND-Study Group, HeuserI, MaierW, LuckhausC, RütherE, HüllM, JahnH, GertzHJ, FrölichL, HampelH, PernetzkiR (2009) Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer’s disease: A multicenter assessment. J Nutr Health Aging13, 205–208.
48.
Shahpasand-KronerH, KlafkiH-W, BauerC, SchuchhardtJ, HüttenrauchM, StaziM, BouterC, WirthsO, VogelgsangJ, WiltfangJ (2018) A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease. Alzheimers Res Ther10, 121.
49.
CostaR, GonçalvesA, SaraivaMJ, CardosoI (2008) Transthyretin binding to A-Beta peptide–impact on A-Beta fibrillogenesis and toxicity. FEBS Lett582, 936–942.
50.
Longo AlvesI, HaysMT, SaraivaMJ (1997) Comparative stability and clearance of [Met30]transthyretin and [Met119]transthyretin. Eur J Biochem249, 662–668.
GerhardtH, SeifertF, BuvariP, VogelsangH, RepgesR (2001) Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol39, 11–17.
54.
GuptaI, GuptaV, PariharA, GuptaS, LüdtkeR, SafayhiH, AmmonHP (1998) Effects of Boswellia serrata gum resin in patients with bronchial asthma: Results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res3, 511–514.
55.
KimmatkarN, ThawaniV, HingoraniL, KhiyaniR (2003) Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee–a randomized double blind placebo controlled trial. Phytomedicine10, 3–7.
56.
DursunE, Gezen-AkD, HanagasıH, BilgicB, LohmannE, ErtanS, AtasoyİL, AlaylıogluM, ArazÖS, ÖnalB, GündüzA, ApaydınH, KızıltanG, UlutinT, GürvitH, YılmazerS (2015) The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer’s disease, mild cognitive impairment or Parkinson’s disease. J Neuroimmunol283, 50–57.
57.
PillaiJA, MaxwellS, BenaJ, BekrisLM, RaoSM, ChanceM, LambBT, LeverenzJB (2019) Key inflammatory pathway activations in the MCI stage of Alzheimer’s disease. Ann Clin Transl Neurol6, 1248–1262.
58.
BettcherBM, KramerJH (2014) Longitudinal inflammation, cognitive decline, and Alzheimer’s disease: A mini-review. Clin Pharmacol Ther96, 464–469.
59.
DikMG, JonkerC, HackCE, SmitJH, ComijsHC, EikelenboomP (2005) Serum inflammatory proteins and cognitive decline in older persons. Neurology64, 1371–1377.
60.
RavagliaG, FortiP, MaioliF, ChiappelliM, MontesiF, TuminiE, MarianiE, LicastroF, PattersonC (2007) Blood inflammatory markers and risk of dementia: The Conselice Study of Brain Aging. Neurobiol Aging28, 1810–1820.
61.
LimaTAS, AdlerAL, MinettT, MatthewsFE, BrayneC, MarioniRE, Medical Research Council Cognitive Function and Ageing Study (2014) C-reactive protein, APOE genotype and longitudinal cognitive change in an older population. Age Ageing43, 289–292.
